PL3140305T3 - Novel compositions, uses and methods for making them - Google Patents

Novel compositions, uses and methods for making them

Info

Publication number
PL3140305T3
PL3140305T3 PL15790016T PL15790016T PL3140305T3 PL 3140305 T3 PL3140305 T3 PL 3140305T3 PL 15790016 T PL15790016 T PL 15790016T PL 15790016 T PL15790016 T PL 15790016T PL 3140305 T3 PL3140305 T3 PL 3140305T3
Authority
PL
Poland
Prior art keywords
making
methods
novel compositions
compositions
novel
Prior art date
Application number
PL15790016T
Other languages
Polish (pl)
Inventor
Mustapha Haddach
Original Assignee
Pimera, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54393079&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL3140305(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pimera, Inc. filed Critical Pimera, Inc.
Publication of PL3140305T3 publication Critical patent/PL3140305T3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
PL15790016T 2014-05-09 2015-05-09 Novel compositions, uses and methods for making them PL3140305T3 (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201461991282P 2014-05-09 2014-05-09
US201462050202P 2014-09-15 2014-09-15
US201462054054P 2014-09-23 2014-09-23
US201562128208P 2015-03-04 2015-03-04
EP15790016.8A EP3140305B1 (en) 2014-05-09 2015-05-09 Novel compositions, uses and methods for making them
PCT/US2015/030046 WO2015172123A1 (en) 2014-05-09 2015-05-09 Novel compositions, uses and methods for making them

Publications (1)

Publication Number Publication Date
PL3140305T3 true PL3140305T3 (en) 2018-10-31

Family

ID=54393079

Family Applications (1)

Application Number Title Priority Date Filing Date
PL15790016T PL3140305T3 (en) 2014-05-09 2015-05-09 Novel compositions, uses and methods for making them

Country Status (33)

Country Link
US (1) US9512123B2 (en)
EP (2) EP3140305B1 (en)
JP (2) JP6188179B2 (en)
KR (3) KR101890505B1 (en)
CN (2) CN106459068B (en)
AU (3) AU2015255738C1 (en)
BR (1) BR112016026150B1 (en)
CA (2) CA2948173C (en)
CL (2) CL2016002798A1 (en)
CY (1) CY1120935T1 (en)
DK (1) DK3140305T3 (en)
EA (1) EA034235B1 (en)
EC (3) ECSP16088687A (en)
ES (1) ES2679628T3 (en)
HR (1) HRP20181105T1 (en)
HU (1) HUE039733T2 (en)
IL (2) IL248638B (en)
LT (1) LT3140305T (en)
MX (1) MX388752B (en)
NI (1) NI201600168A (en)
NZ (1) NZ725917A (en)
PE (2) PE20170131A1 (en)
PH (2) PH12016502213B1 (en)
PL (1) PL3140305T3 (en)
PT (1) PT3140305T (en)
RS (1) RS57493B1 (en)
SG (2) SG10201703658SA (en)
SI (1) SI3140305T1 (en)
SM (1) SMT201800418T1 (en)
TR (1) TR201809990T4 (en)
UA (1) UA117182C2 (en)
WO (1) WO2015172123A1 (en)
ZA (1) ZA201607573B (en)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9758518B2 (en) 2015-03-04 2017-09-12 Pimera, Inc. Compositions, uses and methods for making them
US11912706B2 (en) 2017-03-28 2024-02-27 Pimera, Inc. Crystal forms of a POL1 inhibitor
US11066404B2 (en) 2018-10-11 2021-07-20 Incyte Corporation Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors
US11384083B2 (en) 2019-02-15 2022-07-12 Incyte Corporation Substituted spiro[cyclopropane-1,5′-pyrrolo[2,3-d]pyrimidin]-6′(7′h)-ones as CDK2 inhibitors
TW202100520A (en) 2019-03-05 2021-01-01 美商英塞特公司 Pyrazolyl pyrimidinylamine compounds as cdk2 inhibitors
WO2020205560A1 (en) 2019-03-29 2020-10-08 Incyte Corporation Sulfonylamide compounds as cdk2 inhibitors
US11447494B2 (en) 2019-05-01 2022-09-20 Incyte Corporation Tricyclic amine compounds as CDK2 inhibitors
US11440914B2 (en) 2019-05-01 2022-09-13 Incyte Corporation Tricyclic amine compounds as CDK2 inhibitors
CN112300173B (en) * 2019-07-30 2021-10-01 上海凌达生物医药有限公司 Nitrogen-containing polycyclic compounds, preparation method and application
CN116348458A (en) 2019-08-14 2023-06-27 因赛特公司 Imidazolylpyrimidinylamine compounds as CDK2 inhibitors
CN110606850A (en) * 2019-09-11 2019-12-24 中山大学 A kind of 3-benzo[4,5]imidazo[1,2-a]pyrazine-1-amine compound and its preparation method and application
CN119930611A (en) 2019-10-11 2025-05-06 因赛特公司 Dicyclomine as a CDK2 inhibitor
US20240254117A1 (en) * 2020-12-27 2024-08-01 Shanghai Ringene Biopharma Co., Ltd. Pyrimido-heterocyclic compounds, and preparation method therefor and use thereof
US11981671B2 (en) 2021-06-21 2024-05-14 Incyte Corporation Bicyclic pyrazolyl amines as CDK2 inhibitors
CN113416197B (en) * 2021-08-25 2021-12-28 北京鑫开元医药科技有限公司 Formamide derivatives, preparation method, pharmaceutical composition and application
US11976073B2 (en) 2021-12-10 2024-05-07 Incyte Corporation Bicyclic amines as CDK2 inhibitors
CN114276354B (en) * 2022-01-07 2023-06-02 中山大学 1-aminobenzo [4,5] imidazo [1,2-a ] pyrazine-3-carboxamide compound, preparation and application thereof
CN114539265B (en) * 2022-03-02 2023-07-21 中山大学 Benzimidazolopyrazine-3-carboxamide targeting A2A and its tumor immune function

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL7709746A (en) * 1976-09-09 1978-03-13 Hoechst Ag PROCESS FOR PREPARING BENZIMIDAZO (1,2-A) CHINOLINS.
DE2929414A1 (en) * 1979-07-20 1981-02-05 Hoechst Ag Pyrimido:pyrido:benzimidazole cpds. prepn. - from pyrimidine aldehyde and benzimidazole cpds. and used as optical whitener, dyestuff and photoconductor
DE3502689A1 (en) 1985-01-26 1986-07-31 Hoechst Ag, 6230 Frankfurt ELECTROPHOTOGRAPHIC RECORDING MATERIAL
ATE157665T1 (en) * 1992-06-22 1997-09-15 Boehringer Ingelheim Kg 9-AMINO-PYRIDAZINO 4',5': 3,4>PYRROLO- 2,1- A>ISOCHINOLINES AND THEIR USE FOR THE PRODUCTION OF PHARMACEUTICAL PREPARATIONS
DE19509043A1 (en) * 1995-03-03 1996-09-05 Bayer Ag Cyanation of double bond systems
ATE319713T1 (en) 2000-10-03 2006-03-15 Bristol Myers Squibb Co AMINO-SUBSTITUTED TETRACYCLIC COMPOUNDS USEFUL AS ANTI-INFLAMMATORY AGENTS AND DRUGS CONTAINING SAME.
US7354916B2 (en) 2003-04-07 2008-04-08 Cylene Pharmaceuticals Substituted quinobenzoxazine analogs
US7507727B2 (en) 2003-04-07 2009-03-24 Cylene Pharmaceuticals, Inc. Substituted quinobenzoxazine analogs and methods of using thereof
KR100944600B1 (en) 2003-04-07 2010-02-25 사일린 파마슈티칼스, 인크 Substituted quinobenzoxazine analogs
EP1802306A2 (en) 2004-09-17 2007-07-04 Cylene Pharmaceuticals, Inc. Quinolone analog as cell proliferation inhibitors
US7652134B2 (en) 2004-09-17 2010-01-26 Cylene Pharmaceuticals, Inc. Methods for converting quinolone esters into quinolone amides
ITMI20042476A1 (en) * 2004-12-23 2005-03-23 Cell Therapeutics Europe Srl INDULIC DERIVATIVES WITH ANTITUMOR ACTIVITY
EP1874731A4 (en) 2005-04-15 2009-08-05 Cylene Pharmaceuticals Inc QUINOBENZOXAZINE ANALOGUES AND METHODS OF USE THEREOF
US7816524B2 (en) 2005-08-05 2010-10-19 Cylene Pharmaceuticals, Inc. Methods of preparing quinolone analogs
EP2270014A1 (en) * 2005-09-22 2011-01-05 Incyte Corporation Azepine inhibitors of janus kinases
US8142909B2 (en) 2006-02-10 2012-03-27 Universal Display Corporation Blue phosphorescent imidazophenanthridine materials
CA2651072A1 (en) 2006-05-01 2007-11-08 Pfizer Products Inc. Substituted 2-amino-fused heterocyclic compounds
WO2008060693A2 (en) * 2006-05-17 2008-05-22 Cylene Pharmaceuticals, Inc. Tetracyclic imidazole analogs
DE102006051796A1 (en) 2006-11-03 2008-05-08 Merck Patent Gmbh Triaza-benzo [e] azulene derivatives
CN101888780B (en) * 2007-10-05 2014-08-13 生华生物科技股份有限公司 Quinolone analogs and methods related thereto
JP5576370B2 (en) 2008-08-06 2014-08-20 ファイザー・インク 6-substituted 2-heterocyclylaminopyrazine compounds as CHK-1 inhibitors
US8368062B2 (en) 2008-11-03 2013-02-05 Lg Chem, Ltd. Nitrogen-containing heterocyclic compound and organic electronic device using the same
US8124770B2 (en) 2009-04-01 2012-02-28 Beatriz Zayas Fluorescent cellular markers
CN101781312B (en) * 2009-12-30 2012-09-26 中国科学院广州生物医药与健康研究院 Method for synthesizing derivatives of quinoline or indole
WO2011156698A2 (en) 2010-06-11 2011-12-15 Abbott Laboratories NOVEL PYRAZOLO[3,4-d]PYRIMIDINE COMPOUNDS
WO2012123938A1 (en) * 2011-03-17 2012-09-20 Tel Hashomer Medical Research Infrastructure And Services Ltd. Quinolone analogs for treating autoimmune diseases
KR101561730B1 (en) * 2012-02-06 2015-10-22 주식회사 엘지화학 Nitrogen-containing heterocyclic compound and organic electronic device using the same

Also Published As

Publication number Publication date
CL2016002798A1 (en) 2017-03-10
EP3140305B1 (en) 2018-04-18
IL248638B (en) 2019-02-28
AU2017202145B2 (en) 2019-02-21
UA117182C2 (en) 2018-06-25
AU2017202145A1 (en) 2017-04-20
PT3140305T (en) 2018-07-24
PE20170678A1 (en) 2017-06-03
IL264454A (en) 2019-02-28
CA2974960A1 (en) 2015-11-12
WO2015172123A1 (en) 2015-11-12
CN106995443B (en) 2022-01-11
KR102044648B1 (en) 2019-11-13
NI201600168A (en) 2017-01-26
LT3140305T (en) 2018-09-10
PH12016502213B1 (en) 2018-09-12
SG10201703658SA (en) 2017-06-29
EP3140305A1 (en) 2017-03-15
US20160326176A1 (en) 2016-11-10
JP6188179B2 (en) 2017-08-30
ECSP18049420A (en) 2018-07-31
CA2948173A1 (en) 2015-11-12
DK3140305T3 (en) 2018-07-30
SG11201609171XA (en) 2016-12-29
AU2015255738A1 (en) 2016-11-24
EA201692269A1 (en) 2017-04-28
HRP20181105T1 (en) 2018-09-21
KR101890505B1 (en) 2018-09-28
CN106459068B (en) 2019-01-22
EP3219716A1 (en) 2017-09-20
AU2015255738C1 (en) 2017-09-28
PE20170131A1 (en) 2017-03-19
ES2679628T3 (en) 2018-08-29
CY1120935T1 (en) 2019-12-11
CL2017000372A1 (en) 2017-09-08
KR20170042821A (en) 2017-04-19
SMT201800418T1 (en) 2018-09-13
RS57493B1 (en) 2018-10-31
ZA201607573B (en) 2018-08-30
EA034235B1 (en) 2020-01-20
PH12016502213A1 (en) 2017-01-16
KR20160144509A (en) 2016-12-16
CN106995443A (en) 2017-08-01
MX388752B (en) 2025-03-20
AU2015255738B2 (en) 2017-04-27
MX2016014555A (en) 2017-05-30
CN106459068A (en) 2017-02-22
ECSP17031525A (en) 2017-06-30
BR112016026150B1 (en) 2019-11-05
JP2017101038A (en) 2017-06-08
PH12017500660A1 (en) 2019-03-04
US9512123B2 (en) 2016-12-06
SI3140305T1 (en) 2018-09-28
AU2017203955A1 (en) 2017-07-06
ECSP16088687A (en) 2017-01-31
EP3219716B1 (en) 2024-12-25
KR20180118806A (en) 2018-10-31
CA2948173C (en) 2018-06-19
TR201809990T4 (en) 2018-08-27
EP3140305A4 (en) 2017-03-15
NZ725917A (en) 2017-07-28
JP2017514889A (en) 2017-06-08
HUE039733T2 (en) 2019-01-28

Similar Documents

Publication Publication Date Title
ZA201701168B (en) Antibodies, compositions, and uses
ZA201607573B (en) Novel compositions, uses and methods for making them
SG11201610682UA (en) Ophthalmic composition
GB201410905D0 (en) Composition
GB201501859D0 (en) Composition
SG11201704735WA (en) Composition
GB201403017D0 (en) Composition
ZA201704464B (en) Composition
GB201413216D0 (en) Anti-Dandruff Composition
EP3237399A4 (en) Compounds, compositions and methods
PT3200827T (en) Compositions
GB201414910D0 (en) Composition
GB201403561D0 (en) Composition
PT3217964T (en) Composition
GB201414555D0 (en) Composition
GB201410493D0 (en) Composition
SG11201610547WA (en) Solid composition
GB201404700D0 (en) Novel Composition
GB201519442D0 (en) Composition
GB201404390D0 (en) Composition
ZA201606127B (en) Composition
GB201420628D0 (en) Composition
GB201415483D0 (en) Composition
GB201402648D0 (en) Composition
IL250781A0 (en) Composition